Please login to the form below

Not currently logged in
Email:
Password:

Dr Holger Adelmann joins DIA EMEA

Succeeds Dr Jytte Lynvig as senior vice president and managing director

Dr Holger AdelmannThe DIA (Drug Information Association) has appointed Dr Holger Adelmann as its new senior vice president and managing director for DIA Europe, Middle East and Africa (EMEA).

Dr Adelmann brings nearly 30 years of clinical pharmacology experience to the role at the Washington, DC-headquartered group.

He joined the industry in 1989 and has previously held leading positions at AstraZeneca, Bayer, Merk Serono and Tropon.

Most recently, Dr Adelmann served as the global head of Merck Serono's clinical pharmacology and clinical biomarker operations in Germany.

In that role he oversaw the reengineering of its clinical biomarker and companion diagnostics business to align with upcoming portfolio demands.

Barbara Lopez Kunz, DIA's global chief executive, said: “Holger's diverse background provides us with the leadership necessary to deliver that trusted, future-oriented knowledge and connect the global health care community to this rapidly evolving region.”

Dr Adlemann succeeds Dr Jytte Lynvig who retired from the post earlier this month.

22nd February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics